Pomalyst (pomalidomide) is an oral treatment for multiple myeloma patients whose disease has relapsed or is not responsive to other treatments.| Rare Cancer News
Learn about Darzalex (daratumumab), an antibody therapy approved by the FDA alone or in combination to treat various groups of multiple myeloma patients.| Rare Cancer News
Steve Bryson is a science writer for Myeloma Research News with a PhD in biochemistry. He covers the latest news and information on a variety of myeloma topics.| Rare Cancer News
About 15% relapsed in the first year and patients lived a median of 7.5 years, and without disease progression for a median of three years.| Rare Cancer News
DREAMM-3 did not meet its primary endpoint of progression-free survival (PFS)| www.gsk.com